Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

In development
Reference number: GID-TA11424
Expected publication date: 07 May 2026

Documents

Documents created during the development process.

Draft guidance

Draft guidance
Draft consultation document (online commenting)
Draft consultation document (downloadable version) (PDF 281 KB)

Published:

25 November 2025
Committee papers (PDF 9.28 MB)

Published:

25 November 2025
Public committee slides (PowerPoint 1.33 MB)

Published:

25 November 2025
Equality impact assessment (downloadable version) (PDF 131 KB)

Published:

25 November 2025

Invitation to participate

Final stakeholder list (PDF 134 KB)

Published:

09 January 2025
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 161 KB)

Published:

09 January 2025
Equality impact assessment (scoping) (PDF 100 KB)

Published:

09 January 2025
Final scope (PDF 180 KB)

Published:

09 January 2025

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6442

Draft matrix post referral (PDF 177 KB)

Published:

05 November 2024
Draft scope post referral (PDF 220 KB)

Published:

05 November 2024